Abstract | WHAT IS KNOWN AND OBJECTIVE: METHODS: A comprehensive search for randomized controlled trials (RCTs) evaluating efficacy and safety of interleukin-17 inhibitors was performed through PubMed, Embase and Cochrane Library databases. Quality assessment was performed using the Cochrane Collaboration risk of bias tool. Data were pooled using the fixed or random-effects models. RESULTS AND DISCUSSION: Twenty RCTs were identified: of these 9 studies on patients with AS and 11 studies on patients with PsA. Concerning clinical efficacy, a pooled analysis showed interleukin-17 inhibitors had a higher response rate for the primary endpoint (p < 0.05) and secondary endpoint (p < 0.05) at the treatment endpoint for AS/PsA patients. Moreover, an increased risk of treatment-emergent adverse events and infection was found in AS patients (p < 0.05). In contrast, no increased risk of any adverse events was reported in PsA patients. WHAT IS NEW AND CONCLUSION: In this meta-analysis, our findings found interleukin-17 inhibitors had a significant clinical benefit in the management of AS/PsA patients.
|
Authors | Chongru He, Chenchen Xue, Ge Zhu, Pengde Kang |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 46
Issue 4
Pg. 895-906
(Aug 2021)
ISSN: 1365-2710 [Electronic] England |
PMID | 33768576
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Copyright | © 2021 John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Interleukin-17
- bimekizumab
- brodalumab
- ixekizumab
- netakimab
- secukinumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antirheumatic Agents
(administration & dosage, adverse effects, therapeutic use)
- Arthritis, Psoriatic
(drug therapy)
- Chronic Disease
- Humans
- Interleukin-17
(antagonists & inhibitors)
- Randomized Controlled Trials as Topic
- Rheumatic Diseases
(drug therapy)
- Spondylitis, Ankylosing
(drug therapy)
|